Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 2,852 | 444 | 2,377 |
| Samples | 1,747 | 290 | 1,434 |
| Peptides | 1,434 | 260 | 1,215 |
Function
MYO15A · Myosin XVA
This gene encodes an unconventional myosin. This protein differs from other myosins in that it has a long N-terminal extension preceding the conserved motor domain. Studies in mice suggest that this protein is necessary for actin organization in the hair cells of the cochlea. Mutations in this gene have been associated with profound, congenital, neurosensory, nonsyndromal deafness. This gene is located within the Smith-Magenis syndrome region on chromosome 17. Read-through transcripts containing an upstream gene and this gene have been identified, but they are not thought to encode a fusion protein. Several alternatively spliced transcript variants have been described, but their full length sequences have not been determined. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000647165 | Q9UKN7 | 2,121 | 1,385 |
| ENST00000418233 | Q9UKN7-2 | 385 | 272 |
| ENST00000644795 | A0A2R8Y712* | 346 | 248 |
Gene Properties
Recurrent Mutations
All 1384 amino-acid changes on canonical ENST00000647165 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in MYO15A · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in MYO15A – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 8/40 20% | 0/0 0% |
| Endometrial Carcinoma | 23/42 55% | 57/612 9% |
| Melanoma | 27/210 13% | 211/1899 11% |
| Oral Cavity Carcinoma | 5/54 9% | 0/0 0% |
| Other Solid Cancers | 9/94 10% | 119/1515 8% |
| Glioblastoma | 7/98 7% | 0/0 0% |
| Colorectal Carcinoma | 34/143 24% | 200/3239 6% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 9/133 7% |
| Gastric Carcinoma | 7/74 9% | 120/1809 7% |
| Cervical Carcinoma | 6/35 17% | 21/422 5% |
| Non-Small Cell Lung Carcinoma | 30/304 10% | 51/1390 4% |
| Squamous Cell Lung Carcinoma | 6/57 11% | 33/810 4% |
| Bladder Carcinoma | 6/58 10% | 34/956 4% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Esophageal Squamous Cell Carcinoma | 6/51 12% | 94/2550 4% |
| Acute Myeloid Leukemia | 3/90 3% | 0/0 0% |
| Germ Cell Tumour | 4/25 16% | 2/169 1% |
| Other Sarcomas | 4/69 6% | 19/699 3% |
| Esophageal Carcinoma | 2/23 9% | 21/769 3% |
| Hodgkins Lymphoma | 0/16 0% | 4/122 3% |
| Head and Neck Carcinoma | 5/85 6% | 42/1574 3% |
| Pancreatic Carcinoma | 3/89 3% | 45/1611 3% |
| Neuroendocrine Tumour | 9/154 6% | 11/577 2% |
| Thyroid Gland Carcinoma | 4/45 9% | 40/1592 3% |
| Ewings Sarcoma | 5/63 8% | 3/262 1% |
| Osteosarcoma | 3/45 7% | 2/166 1% |
| Glioma | 3/52 6% | 46/2127 2% |
| Hepatocellular Carcinoma | 6/46 13% | 40/2210 2% |
| Ovarian Carcinoma | 11/109 10% | 11/998 1% |
| Biliary Tract Carcinoma | 1/54 2% | 19/950 2% |
Mutation Distribution
Where MYO15A is mutated · all tissues, split by cell line vs tissue
How many mutations in MYO15A were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 2,852 mutations in MYO15A
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|